Skip to main content

Ask
Past questions
Search
Hearings
Cases
Datasets
Blog
Pricing
Docs

Pernix Therapeutics Holdings, Inc. Bankruptcy Case

P

Pernix Therapeutics Holdings, Inc.

Case No. 19-10323 · Delaware · Petition Date Feb 18, 2019

Ask about this case Track this case View full case profile Get updates on this case

OverviewFilingsPartiesFinancialsPlan

Key Professionals

Financial Advisor

Ernst & Young

Investment Banker

Guggenheim Securities

Investment Banker

Guggenheim Securities, LLC

Debtors Counsel

Landis Rath & Cobb LLP

Coverage

Tracxn·Jul 14, 2025

Skadden, Arps, Slate, Meagher & Flom LLP·Feb 1, 2025

Private Equity | Capabilities | Skadden, Arps, Slate, Meagher & Flom ...

Tobialaw·Feb 6, 2024

2019 Filings in the U.S. Bankruptcy Court for the District of Delaware

Westlaw Today·Mar 19, 2021

McKesson loses bid to claw back funds owed to subsidiary by Orexigen | Business Information & News | FE

Jw·Nov 15, 2019

Healthcare Mergers & Acquisitions Attorneys - Jackson Walker

Curraxpharma·May 1, 2019

Currax™ Holdings USA LLC Announces Launch and Close of ...

Davis Polk·May 1, 2019

Davis Polk Advises Pernix on Completing Sale of Substantially All of ...

Jw·Apr 9, 2019

Venture Capital & Emerging Companies

Davis Polk·Feb 22, 2019

Pernix Enters into an Agreement for the Sale of Substantially All of ...

GlobeNewswire·Feb 19, 2019

Latest News and Press Releases - GlobeNewswire

Bloomberg Law·Feb 19, 2019

Pernix Therapeutics Files Chapter 11 Bankruptcy in Delaware

GlobeNewswire·Feb 19, 2019

Pernix Therapeutics Holdings, Inc. Enters into Asset

petition11.com·Jan 30, 2019

Who Will Remember Things Remembered? - by PETITION LLC

BioWorld·Sep 13, 2018

New beginning for Narachi as Coda debuts with $19M series A +

Ac·Sep 8, 2018

SANG_final_PhD_thesis_after_viva_27333841_completed.pdf

BioSpace·Apr 24, 2018

Orexigen Enters into Agreement to Sell Company to Newly Formed ...

Davis Polk·Jul 26, 2017

Davis Polk Advises Pernix Therapeutics Holdings, Inc. on Its ...

Firstwordpharma·Feb 3, 2017

Pernix Therapeutics Provides Update on Arbitration

BioSpace·Feb 3, 2017

Pernix Provides Update On Arbitration

Abc Amega·Sep 15, 2016

Handout-Lecture-Risk-Mitigation-Tools-NCCA-September-2016-Quarterly-Sept.-23-2016.pdf

Case No.: 19-10323
Court: Delaware
Judge: Christopher S. Sontchi
Petition Date: Feb 18, 2019
Assets: $0-$50,000
Liabilities: $0-$50,000
Industry: Healthcare
Debtors: 14

Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company headquartered in Morristown, New Jersey, focused on developing and commercializing products for underserved market segments, particularly central nervous system indications. The company’s core branded portfolio includes Zohydro ER, Silenor, and Treximet, which collectively accounted for approximately 80% of its 2018 consolidated net product revenues of $138.7 million. Pernix operates through subsidiaries including Macoven Pharmaceuticals and Cypress Pharmaceuticals.